Marie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.
Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.
According to Cabanillas, more options for RET, ALK, and BRAF mutations exist. TRK mutations are another rare fusion requiring an inhibitor. Additionally, there are limitations on the 2 currently approved therapies, sorafenib (Nexavar) and lenvatinib (Lenvima).
For some patients, these therapies are too dangerous, according to Cabanillas. For patients who have a predisposition for bleeding, especially bleeding from the tumor VEGF inhibitors may be unsafe as they may increase bleeding risk. There is a need for more tolerable therapies for this patient population.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Wirth Explores Challenges of Therapy Selection for RAI-Refractory Differentiated Thyroid Cancer
June 28th 2024During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More